Australia markets close in 26 minutes
  • ALL ORDS

    7,330.70
    +23.00 (+0.31%)
     
  • ASX 200

    7,096.90
    +21.80 (+0.31%)
     
  • AUD/USD

    0.6893
    -0.0050 (-0.72%)
     
  • OIL

    108.76
    -1.73 (-1.57%)
     
  • GOLD

    1,806.10
    -2.10 (-0.12%)
     
  • BTC-AUD

    44,128.92
    +807.27 (+1.86%)
     
  • CMC Crypto 200

    682.70
    +1.60 (+0.23%)
     
  • AUD/EUR

    0.6621
    -0.0042 (-0.63%)
     
  • AUD/NZD

    1.1036
    -0.0003 (-0.02%)
     
  • NZX 50

    11,157.66
    -10.52 (-0.09%)
     
  • NASDAQ

    12,387.40
    +441.90 (+3.70%)
     
  • FTSE

    7,418.15
    +184.81 (+2.55%)
     
  • Dow Jones

    32,196.66
    +466.36 (+1.47%)
     
  • DAX

    14,027.93
    +288.33 (+2.10%)
     
  • Hang Seng

    19,921.30
    +22.53 (+0.11%)
     
  • NIKKEI 225

    26,535.73
    +108.08 (+0.41%)
     

CORT vs. ZTS: Which Stock Is the Better Value Option?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Corcept Therapeutics (CORT) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Right now, both Corcept Therapeutics and Zoetis are sporting a Zacks Rank of # 2 (Buy). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that these stocks have improving earnings outlooks. But this is only part of the picture for value investors.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

CORT currently has a forward P/E ratio of 22.36, while ZTS has a forward P/E of 43.46. We also note that CORT has a PEG ratio of 1.59. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ZTS currently has a PEG ratio of 3.11.

Another notable valuation metric for CORT is its P/B ratio of 4.37. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, ZTS has a P/B of 22.75.

These metrics, and several others, help CORT earn a Value grade of B, while ZTS has been given a Value grade of C.

Both CORT and ZTS are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that CORT is the superior value option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report
 
Zoetis Inc. (ZTS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting